Table 2.
Results table for outpatient clinics and cancer types that are treated within each clinic
| Clinic | Material count | About Cancer/Disease | Medical Tests and Imaging | Treatment | Symptom Management | Rehabilitation/Survivorship | General Wellbeing | Medical Device Care | Practical | Other |
|---|---|---|---|---|---|---|---|---|---|---|
| Brain metastases | ||||||||||
| Total | 18 | 8 | 2 | 13 | 12 | 1 | 3 | 0 | 2 | 0 |
| Breast | ||||||||||
| Ductal carcinoma in situ (DCIS) | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Invasive breast cancer (no metastasis) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Invasive breast cancer (metastasis) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| ASCT (general breast) | 50 | 12 | 11 | 28 | 10 | 12 | 13 | 2 | 8 | 0 |
| Total | 52 | 14 | 12 | 30 | 11 | 13 | 14 | 2 | 8 | 0 |
| Endocrine | ||||||||||
| Adrenal | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Parathyroid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pituitary | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Thyroid | 10 | 2 | 6 | 5 | 1 | 1 | 2 | 0 | 1 | 0 |
| ASCT (general endocrine) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 2 | 7 | 8 | 3 | 1 | 2 | 0 | 1 | 0 |
| Gastrointestinal | ||||||||||
| Ampullary | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Anal | 4 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0 | 0 |
| Appendix | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Carcinoid | 4 | 4 | 1 | 3 | 2 | 1 | 2 | 0 | 4 | 0 |
| Colorectal | 13 | 2 | 1 | 5 | 0 | 1 | 2 | 0 | 3 | 3 |
| Esophageal | 4 | 1 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 |
| Gall bladder | 6 | 2 | 0 | 6 | 1 | 0 | 2 | 1 | 0 | 0 |
| Liver | 3 | 1 | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 0 |
| Pancreatic | 7 | 3 | 2 | 6 | 2 | 1 | 1 | 0 | 2 | 0 |
| Stomach | 5 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 1 |
| ASCT (general gastrointestinal) | 10 | 0 | 0 | 7 | 1 | 0 | 0 | 3 | 3 | 0 |
| Total | 57 | 15 | 7 | 37 | 9 | 6 | 11 | 5 | 12 | 4 |
| Genitourinary | ||||||||||
| Bladder | 16 | 1 | 2 | 9 | 1 | 0 | 1 | 6 | 3 | 0 |
| Kidney | 7 | 3 | 2 | 5 | 0 | 0 | 1 | 1 | 2 | 0 |
| Penile | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Prostate | 28 | 7 | 7 | 22 | 7 | 1 | 6 | 1 | 11 | 0 |
| Testicular | 12 | 3 | 2 | 2 | 0 | 2 | 3 | 0 | 3 | 6 |
| ASCT (general genitourinary) | 11 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 2 | 6 |
| Total | 74 | 14 | 13 | 41 | 9 | 3 | 11 | 8 | 21 | 12 |
| Gynecology | ||||||||||
| Cervical | 5 | 3 | 4 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| Uterine | 7 | 1 | 1 | 6 | 1 | 1 | 1 | 0 | 0 | 0 |
| Vulvar | 2 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Vaginal | 3 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 |
| Ovarian | 7 | 4 | 1 | 3 | 1 | 3 | 5 | 0 | 3 | 0 |
| Gestational trophoblastic | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ASCT (general gynecology) | 26 | 2 | 2 | 16 | 16 | 0 | 2 | 0 | 8 | 0 |
| Total | 50 | 11 | 9 | 29 | 21 | 5 | 9 | 0 | 13 | 0 |
| Head and neck | ||||||||||
| Esophageal/tracheal | 5 | 1 | 1 | 3 | 1 | 1 | 1 | 3 | 0 | 0 |
| Laryngeal | 3 | 2 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 0 |
| Oropharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hypopharynx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Oral | 9 | 6 | 1 | 5 | 2 | 1 | 1 | 0 | 4 | 0 |
| Thyroid | 7 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
| ASCT (general head and neck) | 14 | 1 | 0 | 6 | 5 | 2 | 2 | 0 | 6 | 0 |
| Total | 38 | 10 | 8 | 17 | 8 | 5 | 5 | 4 | 13 | 0 |
| Hematology | ||||||||||
| Leukemia | 14 | 10 | 9 | 11 | 1 | 1 | 5 | 0 | 3 | 0 |
| Lymphoma | 8 | 6 | 4 | 6 | 1 | 2 | 3 | 0 | 4 | 0 |
| Multiple myeloma | 21 | 16 | 10 | 20 | 8 | 1 | 6 | 0 | 2 | 0 |
| ASCT (general hematology) | 32 | 6 | 4 | 22 | 11 | 1 | 7 | 0 | 13 | 0 |
| Total | 75 | 38 | 27 | 59 | 21 | 5 | 21 | 0 | 22 | 0 |
| Lung | ||||||||||
| Non-small cell | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Small cell | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Thymoma | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Mesothelioma | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| ASCT (general lung) | 26 | 9 | 8 | 16 | 10 | 3 | 3 | 4 | 2 | 1 |
| Total | 29 | 10 | 9 | 18 | 11 | 4 | 3 | 4 | 2 | 2 |
| Ocular | ||||||||||
| Total | 5 | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 2 | 0 |
| Primary brain cancer | ||||||||||
| Glioblastoma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Meningioma | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pituitary | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ASCT (general primary brain cancer) | 21 | 3 | 7 | 12 | 9 | 2 | 5 | 0 | 7 | 0 |
| Total | 21 | 3 | 7 | 12 | 9 | 2 | 5 | 0 | 7 | 0 |
| Sarcoma | ||||||||||
| Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Skin and melanoma | ||||||||||
| Melanoma | 8 | 6 | 4 | 6 | 3 | 1 | 2 | 0 | 2 | 1 |
| Non-melanoma | 2 | 2 | 2 | 2 | 0 | 1 | 1 | 0 | 0 | 0 |
| ASCT (general skin and melanoma) | 4 | 1 | 0 | 2 | 2 | 0 | 0 | 0 | 2 | 0 |
| Total | 14 | 9 | 6 | 10 | 5 | 2 | 3 | 0 | 4 | 1 |
| Grand total | 447 | 134 | 107 | 277 | 120 | 47 | 87 | 23 | 107 | 19 |
Each outpatient clinic with cancer types are listed, along with corresponding material counts and content counts. Totals for each clinic are listed, along with a final running total for all cancer types treated at the cancer center. A total of 447 PE material titles were found to be distributed across the 13 outpatient clinics. The average number of PE materials available ranged between 0 and 77 across outpatient clinics with an average of 34 PE materials per clinic
ASCT Applicable to Several Cancer Types